Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022

SELL
$26.55 - $40.57 $59,737 - $91,282
-2,250 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$39.27 - $72.94 $58,905 - $109,410
-1,500 Reduced 40.0%
2,250 $92,000
Q1 2021

Apr 26, 2021

BUY
$39.71 - $90.58 $39,710 - $90,580
1,000 Added 36.36%
3,750 $158,000
Q4 2020

Feb 10, 2021

SELL
$27.07 - $84.35 $39,251 - $122,307
-1,450 Reduced 34.52%
2,750 $193,000
Q2 2020

Aug 10, 2020

SELL
$18.5 - $34.34 $46,250 - $85,850
-2,500 Reduced 37.31%
4,200 $124,000
Q4 2019

Feb 11, 2020

BUY
$19.49 - $32.63 $110,703 - $185,338
5,680 Added 556.86%
6,700 $198,000
Q3 2019

Nov 07, 2019

SELL
$22.49 - $26.81 $67,020 - $79,893
-2,980 Reduced 74.5%
1,020 $23,000
Q2 2019

Dec 03, 2019

BUY
$20.48 - $27.76 $81,920 - $111,040
4,000 New
4,000 $99,000
Q2 2019

Jul 30, 2019

SELL
$20.48 - $27.76 $81,920 - $111,040
-4,000 Closed
0 $0
Q1 2019

Dec 03, 2019

BUY
$19.43 - $26.41 $77,720 - $105,640
4,000 New
4,000 $98,000
Q1 2019

May 10, 2019

SELL
$19.43 - $26.41 $31,088 - $42,256
-1,600 Closed
0 $0
Q4 2018

Dec 03, 2019

BUY
$18.19 - $31.79 $29,104 - $50,864
1,600 New
1,600 $36,000
Q4 2018

Jan 31, 2019

SELL
$18.19 - $31.79 $29,104 - $50,864
-1,600 Closed
0 $0
Q3 2018

Dec 03, 2019

BUY
$27.65 - $38.39 $44,240 - $61,424
1,600 New
1,600 $51,000
Q3 2018

Nov 14, 2018

SELL
$27.65 - $38.39 $44,240 - $61,424
-1,600 Closed
0 $0
Q2 2018

Dec 03, 2019

BUY
$31.4 - $41.01 $50,240 - $65,616
1,600 New
1,600 $57,000
Q2 2018

Aug 03, 2018

SELL
$31.4 - $41.01 $50,240 - $65,616
-1,600 Closed
0 $0
Q1 2018

Dec 03, 2019

BUY
$29.84 - $44.08 $47,744 - $70,528
1,600 New
1,600 $53,000
Q1 2018

May 09, 2018

SELL
$29.84 - $44.08 $47,744 - $70,528
-1,600 Closed
0 $0
Q4 2017

Dec 03, 2019

BUY
$21.89 - $31.34 $35,024 - $50,144
1,600
1,600 $49,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $83.2M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.